Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

About this update from Mineralys Therapeutics, Inc.

RADNOR, Pa. , March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025 , at 8:00 a.m. ET . The Launch-HTN trial evaluated the efficacy and safety of lorundrostat, a highly selective aldosterone inhibitor, for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) as an add-on therapy to an existing, prescribed background treatment of two to five antihypertensive medications. The Advance-HTN trial evaluated the efficacy and safety of lorundrostat for the treatment of uHTN or rHTN when used as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications. Monday, March 10 th @ 8:00 a.m. ET Domestic: 1-877-704-4453 International: 1-201-389-0920 Webcast: Link A live webcast of the conference call may also be found on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website. About Mineralys Therapeutics Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania , and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn and Twitter . Contact: Investor Relations [email protected] Media Relations Tom Weible Elixir Health Public RelationsPhone: (1) 515-707-9678Email: [email protected] Source: Mineralys Therapeutics, Inc.

View stock analysis, news, and events for Mineralys Therapeutics, Inc.